Skip to main content
Top
Published in:

28-06-2023 | Hepatitis D

Current and Evolving Management of Chronic Hepatitis Delta Virus (HDV) Infection

Authors: Maria Paola Anolli, Elisabetta Degasperi, Pietro Lampertico

Published in: Current Hepatology Reports | Issue 3/2023

Login to get access

Abstract

Purpose of Review

This review aims to examine the current and evolving management of chronic hepatitis delta virus (HDV) infection, a severe form of viral hepatitis characterized by accelerated liver disease progression, leading to cirrhosis and its complications. Previously, off-label interferon (IFN) administration was the only treatment option for HDV infection, with limited effectiveness and several side effects.

Recent Findings

The discovery of the entry inhibitor bulevirtide (BLV) has been a breakthrough in HDV treatment, showing high rates of viral suppression in clinical trials and in real-life studies. Other compounds, such as lonafarnib and new anti-HBV drugs, are under development to provide alternative or combined treatment strategies.

Summary

Since HDV’s discovery, more than 40 years ago, the current treatment scenario for HDV is rapidly evolving: while BLV is the first approved drug for HDV treatment, with proven effectiveness also in real-life settings, many other compounds are currently under investigation.
Literature
1.
go back to reference Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523–32.PubMedPubMedCentralCrossRef Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523–32.PubMedPubMedCentralCrossRef
2.
go back to reference Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68:512–21.PubMedCrossRef Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68:512–21.PubMedCrossRef
3.
go back to reference Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221:1677–87.PubMedCrossRef Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221:1677–87.PubMedCrossRef
4.
go back to reference Fattovich G, Boscaro S, Noventa F, Pornaro E, Stenico D, Alberti A, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis. 1987;155:931–5.PubMedCrossRef Fattovich G, Boscaro S, Noventa F, Pornaro E, Stenico D, Alberti A, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis. 1987;155:931–5.PubMedCrossRef
5.
6.
go back to reference Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019;19:275–86.PubMedCrossRef Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019;19:275–86.PubMedCrossRef
7.
go back to reference Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies. J Hepatol. 2022;77:1422–30.PubMedCrossRef Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies. J Hepatol. 2022;77:1422–30.PubMedCrossRef
9.
go back to reference European Association for the Study of the Liver European. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370–98. European Association for the Study of the Liver European. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370–98.
10.
go back to reference Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.PubMedCrossRef Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.PubMedCrossRef
11.
go back to reference Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.PubMedCrossRef Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.PubMedCrossRef
12.
go back to reference Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–9.PubMedCrossRef Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–9.PubMedCrossRef
13.
go back to reference Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS ONE. 2014;9:e101002.PubMedPubMedCentralCrossRef Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS ONE. 2014;9:e101002.PubMedPubMedCentralCrossRef
14.
go back to reference Rocco C, Bonavolta R, Vallefuoco L, Braschi U, Sorrentino R, Terracciano D, et al. Comparison of anti-Hepatitis D Virus (HDV) ETI-AB-DELTAK-2 assay and the novel LIAISON® XL MUREX anti-HDV assay in the diagnosis of HDV infection. Diagn Microbiol Infect Dis. 2019;95:114873.PubMedCrossRef Rocco C, Bonavolta R, Vallefuoco L, Braschi U, Sorrentino R, Terracciano D, et al. Comparison of anti-Hepatitis D Virus (HDV) ETI-AB-DELTAK-2 assay and the novel LIAISON® XL MUREX anti-HDV assay in the diagnosis of HDV infection. Diagn Microbiol Infect Dis. 2019;95:114873.PubMedCrossRef
15.
go back to reference Chudy M, Hanschmann KM, Bozdayi M, Kreß J, Nübling M and the Collaborative Study Group. Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays, World Health Organization 2013 https://www.who.int Chudy M, Hanschmann KM, Bozdayi M, Kreß J, Nübling M and the Collaborative Study Group. Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays, World Health Organization 2013 https://​www.​who.​int
16.
go back to reference Pflüger LS, Nörz D, Volz T, Giersch K, Giese A, Goldmann N, et al. Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system. JHEP Rep. 2021;3:100356.PubMedPubMedCentralCrossRef Pflüger LS, Nörz D, Volz T, Giersch K, Giese A, Goldmann N, et al. Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system. JHEP Rep. 2021;3:100356.PubMedPubMedCentralCrossRef
17.
go back to reference Le Gal F, Brichler S, Sahli R, Chevret S, Gordien E. First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology. 2016;64:1483–94.PubMedCrossRef Le Gal F, Brichler S, Sahli R, Chevret S, Gordien E. First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology. 2016;64:1483–94.PubMedCrossRef
18.
go back to reference Bremer B, Anastasiou OE, Ciesek S, Wedemeyer H. Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther. 2019;24:117–23.PubMedCrossRef Bremer B, Anastasiou OE, Ciesek S, Wedemeyer H. Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther. 2019;24:117–23.PubMedCrossRef
19.
go back to reference Anolli MP, Uceda Renteria SC, Degasperi E, Borghi M, Sambarino D, Perbellini R, et al. Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods. Liver Int. 2023; In press Anolli MP, Uceda Renteria SC, Degasperi E, Borghi M, Sambarino D, Perbellini R, et al. Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods. Liver Int. 2023; In press
21.
go back to reference Cornberg M, Lok AS, Terrault NA, Zoulim F. EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference. J Hepatol. 2019;72:539–55.PubMedCrossRef Cornberg M, Lok AS, Terrault NA, Zoulim F. EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference. J Hepatol. 2019;72:539–55.PubMedCrossRef
22.
go back to reference Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol. 2019;70:1008–15.PubMedCrossRef Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol. 2019;70:1008–15.PubMedCrossRef
23.
go back to reference Degasperi E, Loglio A, Scholtes C, Uceda Renteria SC, Charre C, Facchetti F, et al. Divergent patterns of HBV-RNA AND HBcrAg levels in untreated chronic hepatitis delta: a large European cross-sectional study. Dig Liver Dis. 2022;54:S38–9.CrossRef Degasperi E, Loglio A, Scholtes C, Uceda Renteria SC, Charre C, Facchetti F, et al. Divergent patterns of HBV-RNA AND HBcrAg levels in untreated chronic hepatitis delta: a large European cross-sectional study. Dig Liver Dis. 2022;54:S38–9.CrossRef
24.
go back to reference Zhang Z, Ni Y, Lempp FA, Walter L, Mutz P, Bartenschlager R, et al. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. J Hepatol. 2022;77:957–66.PubMedCrossRef Zhang Z, Ni Y, Lempp FA, Walter L, Mutz P, Bartenschlager R, et al. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. J Hepatol. 2022;77:957–66.PubMedCrossRef
26.
go back to reference Brancaccio G, Gaeta GB. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. Int J Antimicrob Agents. 2019;54:697–701.PubMedCrossRef Brancaccio G, Gaeta GB. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. Int J Antimicrob Agents. 2019;54:697–701.PubMedCrossRef
27.
go back to reference Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023;23:117–29.PubMedCrossRef Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023;23:117–29.PubMedCrossRef
28.
go back to reference Wedemeyer H, Schöneweis K, Bogomolov P, Chulanov V, Stepanova T, Viacheslav M, et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with PegInterferon alfa-2a in patients with chronic HBV/HDV coinfection. J Hepatol. 2020;73:S52.CrossRef Wedemeyer H, Schöneweis K, Bogomolov P, Chulanov V, Stepanova T, Viacheslav M, et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with PegInterferon alfa-2a in patients with chronic HBV/HDV coinfection. J Hepatol. 2020;73:S52.CrossRef
29.
go back to reference Asselah A, Stefan Arama S, Bogomolov P, Bourliere M, Fontaine H, Gherlanet GS, et al. Safety and efficacy of bulevirtide monotherapy and in combination with PegInterferon alfa-2a in patients with chronic hepatitis delta: 24-week interim data of MYR204 Phase 2b study. J Hepatol. 2021;75:S291-OS−2717. Asselah A, Stefan Arama S, Bogomolov P, Bourliere M, Fontaine H, Gherlanet GS, et al. Safety and efficacy of bulevirtide monotherapy and in combination with PegInterferon alfa-2a in patients with chronic hepatitis delta: 24-week interim data of MYR204 Phase 2b study. J Hepatol. 2021;75:S291-OS−2717.
30.
go back to reference Lampertico P, Aleman S, Blank A, Bogomolov P, Chulanov V, Mamonova N, et al. Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta. J Hepatol. 2022;77:S828.CrossRef Lampertico P, Aleman S, Blank A, Bogomolov P, Chulanov V, Mamonova N, et al. Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta. J Hepatol. 2022;77:S828.CrossRef
31.
go back to reference • Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogolomov P, et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study. J Hepatol. 2022;77:S4. Phase 3 study about BLV treatment in HDV patients.CrossRef • Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogolomov P, et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study. J Hepatol. 2022;77:S4. Phase 3 study about BLV treatment in HDV patients.CrossRef
32.
go back to reference Allweiss L, Volmari A, Ladiges Y, Eggers C, Giersch K, Schoneweis K, et al. Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with bulevirtide in chronic HBV/HDV co-infected patients: interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301). Hepatology. 2021;74:148. Allweiss L, Volmari A, Ladiges Y, Eggers C, Giersch K, Schoneweis K, et al. Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with bulevirtide in chronic HBV/HDV co-infected patients: interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301). Hepatology. 2021;74:148.
33.
go back to reference Lampertico P, Aleman S, Asselah T, Bourliere M, Streinu-Cercel A, Bogomolov P, et al. Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2mg and 10 mg dose for treatment of chronic hepatitis delta. J Hepatol. 2022;77:S829.CrossRef Lampertico P, Aleman S, Asselah T, Bourliere M, Streinu-Cercel A, Bogomolov P, et al. Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2mg and 10 mg dose for treatment of chronic hepatitis delta. J Hepatol. 2022;77:S829.CrossRef
34.
go back to reference Buti M, Wedemeyer H, Aleman S, Chulanov V, Morozov V, Sagalova O, et al. Bulevirtide improves health related quality life measured by EQ-5D VAS in patients with chronic hepatitis delta: an exploratory analysis of a phase 3 trial at 48 weeks. Hepatol. 2022;76:S224. Buti M, Wedemeyer H, Aleman S, Chulanov V, Morozov V, Sagalova O, et al. Bulevirtide improves health related quality life measured by EQ-5D VAS in patients with chronic hepatitis delta: an exploratory analysis of a phase 3 trial at 48 weeks. Hepatol. 2022;76:S224.
35.
go back to reference Zoulim F, Fougerou-Leurent C, Roulot D, Metivier S, De Ledinghen V, Ratziu V, et al. Real-life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort. Delta Cure 1st International Meeting, Poster #36 Zoulim F, Fougerou-Leurent C, Roulot D, Metivier S, De Ledinghen V, Ratziu V, et al. Real-life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort. Delta Cure 1st International Meeting, Poster #36
36.
go back to reference De Lédinghen V, Metivier S, Bardou-Jacquet E, Hilleret MN, Loustaud-Ratti V, Ganne-Carrié N, et al. Treatment with bulevirtide in patients with chronic HBV/HDV coinfection. Safety and efficacy at month 18 in real-world settings. J Hepatol. 2022;77:840.CrossRef De Lédinghen V, Metivier S, Bardou-Jacquet E, Hilleret MN, Loustaud-Ratti V, Ganne-Carrié N, et al. Treatment with bulevirtide in patients with chronic HBV/HDV coinfection. Safety and efficacy at month 18 in real-world settings. J Hepatol. 2022;77:840.CrossRef
37.
go back to reference •• De Lédinghen V, Hermabessière P, Metivier S, Bardou Jacquet E, Hilleret MN, Loustaud Ratti V, et al. Bulevirtide, with or without Peg-Interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program. Hepatol. 2022;76:S26–7. Real-life French study evaluating effectiveness of BLV and BLV + PegIFNα treatment up to two years. •• De Lédinghen V, Hermabessière P, Metivier S, Bardou Jacquet E, Hilleret MN, Loustaud Ratti V, et al. Bulevirtide, with or without Peg-Interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program. Hepatol. 2022;76:S26–7. Real-life French study evaluating effectiveness of BLV and BLV + PegIFNα treatment up to two years.
39.
go back to reference Jachs M, Schwartz C, Panzer M, Binter T, Aberle SW, Hartl L, et al. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a “real world” study. Aliment Pharmacol Ther. 2022;56:144–54.PubMedPubMedCentralCrossRef Jachs M, Schwartz C, Panzer M, Binter T, Aberle SW, Hartl L, et al. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a “real world” study. Aliment Pharmacol Ther. 2022;56:144–54.PubMedPubMedCentralCrossRef
40.
go back to reference •• Degasperi E, Anolli MP, Uceda Renteira SC, Sambarino D, Borghi M, Perbellini R, et al. Bulevirtide monotherapy for 48 weeks in HDV patients with compensated cirrhosis and clinically significant portal hypertension. J Hepatol. 2022;77:1525–31. Real-life Italian study evaluating effectiveness of BLV monotherapy in HDV patients with cirrhosis and clinically significant portal hypertension.PubMedCrossRef •• Degasperi E, Anolli MP, Uceda Renteira SC, Sambarino D, Borghi M, Perbellini R, et al. Bulevirtide monotherapy for 48 weeks in HDV patients with compensated cirrhosis and clinically significant portal hypertension. J Hepatol. 2022;77:1525–31. Real-life Italian study evaluating effectiveness of BLV monotherapy in HDV patients with cirrhosis and clinically significant portal hypertension.PubMedCrossRef
41.
go back to reference Anolli MP, Degasperi E, D’Offizi G, Brunetto MR, Verucchi G, Federico A, et al. Extension of bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis. Efficacy and safety from the Italian multicenter study (HEP4Di). Dig Liver Dis. 2023;55:S7.CrossRef Anolli MP, Degasperi E, D’Offizi G, Brunetto MR, Verucchi G, Federico A, et al. Extension of bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis. Efficacy and safety from the Italian multicenter study (HEP4Di). Dig Liver Dis. 2023;55:S7.CrossRef
42.
go back to reference • Anolli MP, Degasperi E, Allweiss L, Sangiovanni A, Maggioni M, Scholtes C, Oberhardt V, Neumann-Haefelin C, Dandri M, Zoulim F, Lampertico P. A 3-year course of Bulevirtide monotherapy may cure HDV infection in patients with cirrhosis. J Hepatol. 2023;78(4):876–80. https://doi.org/10.1016/j.jhep.2022.12.023. First case report describing a potential HDV cure in a patient with compensated cirrhosis treated with BLV monotherapy.CrossRef • Anolli MP, Degasperi E, Allweiss L, Sangiovanni A, Maggioni M, Scholtes C, Oberhardt V, Neumann-Haefelin C, Dandri M, Zoulim F, Lampertico P. A 3-year course of Bulevirtide monotherapy may cure HDV infection in patients with cirrhosis. J Hepatol. 2023;78(4):876–80. https://​doi.​org/​10.​1016/​j.​jhep.​2022.​12.​023. First case report describing a potential HDV cure in a patient with compensated cirrhosis treated with BLV monotherapy.CrossRef
43.
go back to reference Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018;67:1224–36.PubMedCrossRef Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018;67:1224–36.PubMedCrossRef
44.
go back to reference Yurdaydin C, Keskin O, Yurdcu E, Çalişkan A, Önem S, Karakaya F, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2022;75:1551–65.PubMedCrossRef Yurdaydin C, Keskin O, Yurdcu E, Çalişkan A, Önem S, Karakaya F, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2022;75:1551–65.PubMedCrossRef
45.
go back to reference Yurdaydin C, Yurdcu E, Gumussoy M, Keskin O, Gencdal G, Akyildiz M, et al. Functional cure with lonafarnib-based therapy in chronic hepatitis delta. Hepatol. 2022;76:S297. Yurdaydin C, Yurdcu E, Gumussoy M, Keskin O, Gencdal G, Akyildiz M, et al. Functional cure with lonafarnib-based therapy in chronic hepatitis delta. Hepatol. 2022;76:S297.
46.
go back to reference Etzion O, Hamid SS, Lurie Y, Gane E, Bader N, Yardeni D, et al. End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. J Hepatol. 2019;70:e32.CrossRef Etzion O, Hamid SS, Lurie Y, Gane E, Bader N, Yardeni D, et al. End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. J Hepatol. 2019;70:e32.CrossRef
47.
go back to reference Duehren S, Koh C, Hercun J, Rahman F, Surana P, Vittal A, et al. Lonafarnib combination with PegInterferon lambda diminished triphasic HDV kinetic pattern seen under Lambda monotherapy: the LIFT HDV study. J Hepatol. 2022;77:S70.CrossRef Duehren S, Koh C, Hercun J, Rahman F, Surana P, Vittal A, et al. Lonafarnib combination with PegInterferon lambda diminished triphasic HDV kinetic pattern seen under Lambda monotherapy: the LIFT HDV study. J Hepatol. 2022;77:S70.CrossRef
48.
go back to reference Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022;77:1287–98.PubMedCrossRef Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022;77:1287–98.PubMedCrossRef
49.
go back to reference Agarwal K, Buti M, Van Bammel F, Lampertico P, Janczewska E, Bourliere M, et al. Efficacy and safety of combination treatment with siRNA JHJ-73763989 and capsid assembly modulator JNJ-56136379 (Bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B patients: follow-up week 48 end of study results from REEF-2. Late Breaking Abstracts of the 2022 AASLD Liver Meeting, November 4–6, 2022. Washington, DC Agarwal K, Buti M, Van Bammel F, Lampertico P, Janczewska E, Bourliere M, et al. Efficacy and safety of combination treatment with siRNA JHJ-73763989 and capsid assembly modulator JNJ-56136379 (Bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B patients: follow-up week 48 end of study results from REEF-2. Late Breaking Abstracts of the 2022 AASLD Liver Meeting, November 4–6, 2022. Washington, DC
50.
go back to reference Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158:2180–94.PubMedCrossRef Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158:2180–94.PubMedCrossRef
Metadata
Title
Current and Evolving Management of Chronic Hepatitis Delta Virus (HDV) Infection
Authors
Maria Paola Anolli
Elisabetta Degasperi
Pietro Lampertico
Publication date
28-06-2023
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 3/2023
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-023-00606-7

Other articles of this Issue 3/2023

Current Hepatology Reports 3/2023 Go to the issue

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more